`Qiqing Baidu Tablets Veterinary Grade API` is a standardized multi-herb extract powder supplied for incorporation into tablets, injections, capsules, powders, granules, premixes, and solutions under veterinary good manufacturing practice. The material is not a finished dosage form; it is an active pharmaceutical ingredient whose native plant matrix has been extracted, concentrated, dried, milled, and normalized to a chromatographic profile. In batch documentation, the model designation is written as QBD-API with a suffix indicating the intended dosage-form route — TAB, INJ, CAP, PWD, GRN, PREMIX, or SOL. The suffix does not identify a separate chemical entity. Because the API is a multicomponent botanical extract, release does not rely on a single-analyte purity value; instead, identity is established by thin-layer chromatographic zones and a high-performance liquid chromatography fingerprint compared with the retained reference extract.

The powder is processed to a controlled particle-size band so that the same API can be dry-blended for premixes or wet-granulated for tablets without an additional micronization step. For representative bulk material, the volume mean diameter is typically 45–90 µm by laser diffraction under ISO 13320:2020; the powder passes through an 80 mesh (180 µm) screen at not less than 90%. These physical limits are selected to balance flowability against blend homogeneity in low-dose tablet and premix applications. Because residual moisture accelerates polyphenol oxidation, the material is packed in double polyethylene bags inside a fibre drum and stored at 15–25 °C with relative humidity below 60%.

As a veterinary-grade multi-herb extract, the product carries the same name as the traditional formulation but is not equivalent to a simple comminuted herb powder. The extraction and drying step reduces the inclusion volume required in final formulations and removes a portion of the plant fibre that would otherwise interfere with tablet compression. The concentration ratio is expressed as a native extract ratio or as a marker-content range on the certificate of analysis. Published data for the specific extract ratio of this commercial product is limited; therefore, a purchase specification should require the supplier to state the native extract ratio and marker acceptance band for each batch.

What Belongs in the Certificate of Analysis for a Multi-Dosage-Form Veterinary API?

A competent release certificate for this material should separate the criteria into identification, purity, physical, and microbiological groups. The identification group is more complex than a single chemical assay. The high-performance liquid chromatographic fingerprint should match the reference chromatogram, with a similarity index of not less than 0.95 when computed by the pharmacopoeial method of Ph. Eur. 2.2.29 or USP <621>. Thin-layer chromatographic identity is performed on silica gel 60 F254 plates; the principal zones must correspond in position and colour to the reference extract. Marker content is not a single purity number but a defined ratio of at least two or three marker peaks; the acceptance band is lot-specific and must be declared on the certificate.

The limits shown above are representative release criteria for botanical veterinary APIs derived from aqueous or hydroalcoholic extracts. They are not a substitute for the marketing authorization or the manufacturer’s filed specification. Where injection-grade material is purchased, the bacterial endotoxin limit is mandatory; where only oral powders or premixes are produced, the same limit may be waived unless the receiving site is handling parenteral product. Heavy metals and arsenic are controlled because the source plant material may accumulate soil contaminants; inductively coupled plasma mass spectrometry is used where the sample matrix interferes with the colorimetric limit test.

Processing Windows in Wet Granulation and Direct Compression Lines

Wet granulation is preferred when the API fraction in the tablet core exceeds 10 wt% because the botanical extract shows cohesive behaviour under direct compression. In a 10 L high-shear granulator, the dry blend is premixed for 3–5 min at an impeller speed of 200–300 rpm and a chopper speed of 1,500 rpm. The binder, typically a 5–10% w/w hydroxypropyl cellulose solution in purified water, is added at 10–20 g/min. The wet mass endpoint is set when the impeller power draw rises 12–18% above the dry-mix baseline. The power-draw endpoint is more reproducible than visual assessment for this extract because the colour change during wetting is minimal.

After granulation, the mass is dried in a fluid-bed dryer at an inlet air temperature of 60–70 °C until the final loss on drying is 2.5–4.5%. Higher residual moisture produces picking and sticking during compression; lower moisture increases friability and edge chipping. The dried granulate is milled through a 1.0 mm screen and then blended with disintegrant and lubricant. The resulting granulate should have a bulk density of 0.45–0.60 g/mL and a Carr index of 15–25% as calculated from USP <616>. Compression on a rotary tablet press is typically performed at 35–60 rpm with a compression force of 8–14 kN, producing tablets with hardness 60–90 N and friability below 1.0% when tested under USP <1216> or Ph. Eur. 2.9.7.

The hygroscopic nature of the dried extract creates a narrow processing window in humid production halls. When ambient relative humidity exceeds 60%, the granulate absorbs moisture and the Carr index may increase by 5–10 percentage points within 30 min, causing weight variation on the tablet press. This was observed on rotary presses with paddle feeders when the feed frame was not humidity-controlled. To avoid this, the discharge air from the fluid-bed dryer is monitored at ≤ 45% RH, and the compression room is kept under a negative pressure differential of 10–15 Pa relative to adjoining corridors. These observations are line-specific and are not a substitute for production-scale qualification.

Direct compression is feasible only when the API content is low, typically below 5 wt%, because higher levels reduce tablet tensile strength. In direct compression trials, the extract powder exhibits a compactability deficit attributed to the glass transition of the amorphous botanical solids; when the compaction pressure exceeds 150 MPa, capping is observed. Therefore, direct compression formulations are limited to low-dose tablets and require a filler with plastic deformation characteristics, such as microcrystalline cellulose, at 60–70% of the formulation. Higher filler levels may be required for capsules or premixes where the active fraction is low.

For dry blends and premixes, the API may be added directly if the dose is sufficiently high; however, electrostatic charging of the fine extract powder can reduce blend uniformity. The standard approach is to pre-blend the API with a portion of carrier at a 1:3 ratio in a tumble blender for 10 min, then pass through a 0.5 mm sieve before the final blend. Blend uniformity is evaluated using USP <905>, with ten samples meeting assay values of 90.0–110.0% and relative standard deviation not exceeding 5.0%. Premix carriers such as corn cobs or lactose are dried to moisture below 5.0% before use.

In capsule filling operations, the granulated or powder blend is passed through a 0.8 mm screen immediately before transfer to the hopper. The filling room is maintained at 20–25 °C and 35–45% RH; exposure above 50% RH is limited to 30 min because the extract becomes tacky. Capsule fill weight variation is monitored at start-up and every 15 min thereafter, with acceptance limits of ±5.0% from target for individual capsules and ±2.5% for the sample mean. Powder slugging in the dosator is controlled by adding colloidal silicon dioxide at 0.2–0.5 wt%; higher levels reduce dissolution and are avoided unless the dissolution profile under USP <711> remains within the authorized acceptance range.

When the Same API Is Compounded into Injectable or Solution Dosage Forms

Injectable processing requires a different control set from tablet or premix manufacture. The injection-grade powder is specified for bacterial endotoxins below 0.5 EU/mg by USP <85>, and the receiving cleanroom is classified under ISO 14644-1; a Grade C or Grade B environment is used for solution preparation and filtration, depending on the sterilization strategy. The API is not directly compressed; instead, it is dissolved or suspended in water for injection at a temperature not exceeding 40 °C, then clarified through a 0.45 µm membrane and sterilized through a 0.22 µm membrane. For solutions, pH is adjusted to 6.5–7.5 with 1 M sodium hydroxide or 1 M hydrochloric acid unless the marketing authorization specifies a narrower range.

Particulate matter in the finished injection is controlled under USP <788>: for small-volume parenterals, not more than 6,000 particles per container at ≥ 10 µm and not more than 600 particles per container at ≥ 25 µm. Terminal sterilization at 121 °C for 15 min is acceptable when the formulation has an F0 ≥ 8.0; when heat-sensitive marker compounds are present, aseptic filtration is used instead. Published data for the specific heat-lability of Qiqing Baidu marker compounds is limited; therefore, terminal sterilization must be validated by marker recovery and chromatographic fingerprint after the cycle.

The bacterial endotoxin limit is not merely a release test; it is a process control that depends on the water used in manufacture and the bioburden of the extract. For injection-grade campaigns, the API is dissolved in endotoxin-free water for injection, and the solution is held for not more than 4 h before filtration to limit microbial growth. The filtration train is integrity-tested before and after use according to the supplier’s bubble-point method or ASTM F838-20. If the final solution is not terminally sterilized, the aseptic filling line is qualified by media-fill studies with fill volumes representative of the marketed container.

For oral solutions and drinking-water premixes, the API is pre-wetted with 10–20% of the final volume of 95% ethanol or propylene glycol to avoid floating and clumping. Water is then added with continuous mixing at 200–400 rpm; heating above 40 °C is avoided because it may accelerate degradation of alkaloid markers. The solution is filtered through a 10 µm or 5 µm clarifying filter before filling; a 0.45 µm membrane is used only when microbial control requires it, because adsorption of polyphenols onto nylon membranes can reduce marker recovery. The dilution water is adjusted to pH 5.5–7.0; hard water exceeding 200 ppm CaCO₃ is softened before mixing because polyvalent cations can precipitate polyphenolic fractions. Solutions are protected from light and used within the stability window stated in the veterinary authorization.

How Does the Veterinary API Differ from Crude Herbal Powders and Single-Entity Chemical APIs?

The comparison is not based on a single assay value but on the manufacturing controls and the intended dosage-form range. A crude herbal powder is typically produced by drying and comminution without extraction and standardization; its microbial load, particle size, and marker content are variable. A single-entity chemical API such as florfenicol or doxycycline is chemically defined and can be released against a purity assay. This product occupies an intermediate class: it is a standardized multi-herb extract that must be released against a chromatographic fingerprint, marker ratio, and physical limits rather than a single purity figure.

For veterinary manufacturers, the most important differentiation is that feed-grade material should not be substituted for API-grade material in tablets or injectables without a full risk assessment. The API-grade powder is processed under written batch records and is intended to meet ICH Q7 principles for active pharmaceutical ingredients; the feed-grade powder may not be manufactured under the same controls. Finished dosage form manufacture must also comply with 21 CFR 210/211 as applicable to the veterinary product registration. Batch-to-batch fingerprint variation remains an operational boundary because raw botanical inputs are natural products. Buyers should specify a reference chromatogram and a marker acceptance band in the purchase specification, and should require a certificate of analysis that lists the actual batch results for the above-mentioned tests rather than compendial minimums alone.